LGALS3 and anaplastic cancer: To further confirm the expression patterns of Galectin-3 in thyroid cancer, we conducted immunohistochemistry in 20 surgical specimens, including 19 pathology-confirmed papillary thyroid cancer samples and 1 anaplastic cancer sample.